Press Releases

May 06, 2020
Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 ALPHA2 Trial for ALLO-501A, the Next Generation anti-CD19 AlloCAR T™ Intended for Phase 2
Apr 29, 2020
Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T Therapy ALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion Platform Phase 1 Study Continues Enrollment to Optimize Lymphodepletion SOUTH SAN
Displaying 11 - 20 of 21
Print Page
Email Alerts
RSS Feeds
Investor Contacts